Atherosclerosis, the gradual buildup of cholesterol-laden plaques inside artery walls, has long been understood as a disease of lipids. But cardiologists increasingly recognize chronic inflammation as its silent engine. Inflammatory markers predict cardiovascular risk independently of LDL cholesterol levels, and landmark trials of anti-inflammatory drugs have shown that taming the immune response can reduce cardiac events even when cholesterol is already controlled. The new study taps directly into this shift, asking whether a dietary compound could achieve what drugs have only partially delivered: suppressing the chronic, low-grade inflammation that drives plaque development before it starts.

The research team, led by scientists affiliated with Xiamen University, turned to low-density lipoprotein receptor knockout (LDLR−/−) mice, a classic model of human atherosclerosis in which the absence of the LDL receptor causes rapid accumulation of plasma LDL cholesterol and accelerated deposition in the arterial wall. Forty male mice, seven weeks old at arrival, were randomized into five groups after a week of adaptive feeding. Eight animals received a normal diet, while the remaining thirty-two were placed on a high-cholesterol diet containing just over 20% fat and 1.25% cholesterol. Three of these groups also received daily oral doses of 3′-SL at 40.5, 81.0, or 162.0 milligrams per kilogram of body weight, a range selected by allometric scaling from an established effective dose of free sialic acid and well below the compound’s reported no-observed-adverse-effect level of more than 2,000 milligrams per kilogram per day. The intervention continued for twelve weeks.

The results were striking and dose-dependent. Mice receiving 3′-SL showed significantly reduced lipid deposition in the aorta, visualized by Oil Red O staining of the full length of the vessel from the ascending arch to the iliac bifurcation. Blood chemistry told a parallel story: triglycerides fell in all intervention groups, LDL cholesterol declined in a clear dose–response relationship, and HDL—the “good” cholesterol—rose significantly. In the highest-dose group, total cholesterol also dropped. Meanwhile, oral glucose tolerance improved across the treatment groups, suggesting the compound’s benefits extended beyond lipid handling alone.

The inflammatory signature changed just as dramatically. High-cholesterol feeding elevated serum levels of pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-alpha (TNF-α). Supplementation with 3′-SL reversed this pattern, significantly lowering IL-6 and IL-1β across intervention groups, reducing TNF-α at medium and high doses, and boosting the anti-inflammatory cytokine IL-10. Because IL-6 and IL-1β are independently associated with elevated cardiovascular risk in human studies, this cytokine shift represents a potentially meaningful cardioprotective change, not merely a biochemical curiosity.

To understand how a milk sugar could accomplish all this, the investigators deployed a multi-omics arsenal: 16S rDNA sequencing of colon contents to map the gut microbiota, RNA sequencing of colonic tissue to capture transcriptional changes, and ultra-high-performance liquid chromatography–tandem mass spectrometry to profile the colonic metabolome. Using the medium-dose group as the representative cohort for mechanistic analysis, they found that 3′-SL substantially reshaped the microbial ecosystem. The abundance of Firmicutes—a phylum that expanded under the high-cholesterol diet—fell, while Verrucomicrobiota and Bacteroidetes rose, correcting the Firmicutes-to-Bacteroidetes ratio that has been repeatedly linked to obesity, metabolic disease, and atherosclerosis. At the genus level, the beneficial microbe Akkermansia expanded notably.

Akkermansia muciniphila has earned a reputation as an “intestinal guardian” in the microbiome literature. It feeds on the mucus layer lining the gut, stimulates the expression of tight junction proteins such as Occludin and Claudin-1, and releases outer membrane vesicles that reinforce the epithelial barrier. A sturdier barrier means fewer microbial endotoxins leaking into the bloodstream—an important source of the systemic inflammation that stokes arterial damage. Akkermansia also promotes short-chain fatty acid production, which dampens inflammatory signaling through G protein-coupled receptors on macrophages and intestinal epithelial cells, inhibiting the NF-κB pathway and reducing IL-6 secretion. Consistent with these mechanisms, the researchers observed that microbial correlations with serum IL-1β weakened after intervention while correlations with anti-inflammatory IL-10 strengthened, and the gut microbial structure of treated mice shifted toward that of the normal-diet controls.

The transcriptomic and metabolomic data added a deeper layer of mechanistic detail. Colonic tissue from treated mice showed differential expression of genes involved in immune regulation and lipid metabolism, including Ccl2, Il2ra, Kng1, and the complement component gene C6. Differential metabolites—ranging from lipid species to vitamin D derivatives and amino acid compounds—showed significant correlations with these immune- and cardiovascular-related genes. Among the findings, one molecule stands out as the linchpin of the study: Ccl2, better known as monocyte chemoattractant protein-1 (MCP-1). This chemokine recruits monocytes and macrophages into the subendothelial space of artery walls, the critical initiating step in foam cell formation and plaque development. The researchers found that 3′-SL suppressed Ccl2 expression, suggesting that gut-derived, anti-inflammatory metabolites entering the circulation may directly throttle the recruitment of inflammatory cells into the vasculature. Changes in Kng1 hint at additional benefits through the kinin system—potentially improving vascular tone and endothelial function—while effects on C6 suggest reduced complement-mediated damage to the endothelium via the membrane attack complex.

Taken together, the data sketch a coherent causal chain the authors call the “gut-immune-cardiovascular axis.” A high-cholesterol diet disrupts the gut microbiome, weakening the intestinal barrier and activating mucosal immune cells that seed systemic inflammation. 3′-SL, arriving intact in the colon after passing through the small intestine, feeds beneficial bacteria, restores microbial balance, strengthens the barrier, and recalibrates the metabolite pool. Those metabolites and immune signals then converge on the vascular wall, where reduced MCP-1 expression means fewer monocytes infiltrating the artery lining and fewer plaques taking root. The study’s integrated pathway analysis showed that the top enriched KEGG pathways among differential genes and metabolites involved immune regulation, inflammatory response, energy metabolism, lipid metabolism, and hormone synthesis—all processes implicated in the transition from metabolic stress to arterial disease.

The findings arrive amid growing enthusiasm for human milk oligosaccharides as functional food ingredients. 3′-SL is already recognized as safe by the U.S. FDA and approved as a novel food in the European Union, and a clinical trial in dyspeptic patients with Helicobacter pylori infection found doses up to 20 grams per day for four weeks to be well tolerated. Previous work has suggested the sugar can promote the growth of anti-inflammatory bacteria such as Faecalibacterium prausnitzii and Blautia in fecal communities from pediatric Crohn’s disease patients, and that it synergizes with Bifidobacterium infantis to alleviate intestinal inflammation through cross-feeding mechanisms that generate short-chain fatty acids. The current study extends this portfolio into cardiovascular territory, providing what the authors describe as robust preclinical evidence for gut-microbiota-targeted nutritional intervention against atherosclerosis.

Still, the researchers are careful about the limits of their work. The experiment used only male mice, leaving open whether hormonal cycles in females might alter the response, since estrogen and progesterone influence lipid metabolism, inflammation, and microbiome composition. The multi-omics analysis revealed correlations, not proven causation; future experiments such as fecal microbiota transplantation would be needed to establish that the reshaped microbiome itself drives the cardioprotection. Dosing also remains unresolved for humans—the mouse doses used translate to roughly 6.5 to 26 grams per day for a 60-kilogram adult by allometric scaling, and no clinical trials have yet tested 3′-SL for cardiovascular prevention. Patients with inflammatory bowel disease, whose permeable and inflamed guts may respond differently, warrant particular caution and dedicated trials before supplementation could be recommended.

Even with those caveats, the study marks a compelling proof of concept: a molecule designed by evolution to nourish infant guts may also defend adult arteries. As the global burden of atherosclerotic cardiovascular disease continues to climb, and as statins leave a residual inflammatory risk untouched in millions of patients, the idea that a prebiotic sugar could intercept the disease at its immunological source—via the gut—is precisely the kind of accessible, food-based strategy that prevention medicine has been searching for. The next step, translating the gut-immune-cardiovascular axis from mouse models to human trials, will determine whether breast milk’s lesser-known sugar becomes a genuine weapon against heart disease.

The intricacies of lipid metabolism are profound and involve numerous proteins, each serving unique functions in the overall systemic process. HDL particles are often referred to as “good” cholesterol due to their ability to transport cholesterol away from the arteries and back to the liver. This transportation mechanism not only prevents atherosclerosis but also contributes to a range of other cardiovascular benefits. Understanding the nuanced interactions between HDL particles and regulatory proteins is essential for developing therapeutic strategies targeting cardiovascular diseases.

Wang et al. focused specifically on β2GPI, a multifaceted protein traditionally known for its affinity to phospholipids and role in the immune system. Their research suggests that β2GPI acts beyond its conventional roles, emerging as a novel regulator for ApoE-containing HDL particles. This revelation opens new pathways for understanding how HDL functionality is influenced by various proteins, a significant factor given that cardiovascular disease risk can differ based on sex and hormonal factors.

The research indicates that the presence of β2GPI enhances the formation and stability of ApoE-containing HDL particles in female populations, which has vital implications for female cardiovascular health. Historically, cardiovascular research has often overlooked the distinctive differences between sexes, leading to a generalized understanding that may not accurately reflect the complexities involved. This study highlights the importance of integrating sex-specific biological factors into research, shedding light on how female physiology may uniquely respond to lipid regulation.

In laboratory conditions, researchers observed that the inclusion of β2GPI in HDL particles significantly enhanced their anti-inflammatory properties. This feature is particularly beneficial, given that inflammation plays a critical role in the development of cardiovascular diseases. The enhanced anti-inflammatory potential of β2GPI-modulated HDL could also inform future therapeutic avenues, where the goal would be to augment HDL functionality in patients with inflammatory diseases or those at high risk for cardiovascular events.

Further analyses revealed a direct relationship between β2GPI levels and the efficiency of lipid transport mediated by ApoE. High levels of β2GPI correlated with increased ApoE expression, suggesting that the protein may play a crucial role in the biogenesis and secretion of HDL particles from hepatic cells. This finding points to β2GPI not just as a facilitator but potentially as a key player influencing how effectively the body manages cholesterol levels, particularly in women who display different lipid profiles compared to men.

Interestingly, the research illuminated the specific pathways through which β2GPI engages with HDL particles. The binding interactions between β2GPI and ApoE-containing HDL were elucidated, enabling researchers to identify mechanisms that might be manipulated for therapeutic benefits. Modulating these pathways could lead to innovative strategies in managing dyslipidemia, particularly in populations traditionally underrepresented in clinical studies.

The implications of this research extend beyond academic intrigue, with potential clinical applications spanning preventive cardiology and targeted therapeutics aimed at modulating HDL functionality. As cardiovascular diseases remain a leading cause of morbidity and mortality worldwide, understanding the biological underpinnings of HDL regulation could pave the way for significant advancements in treatment protocols.

Moreover, the emergence of biomarkers derived from this research could facilitate the early detection of cardiovascular risk, aiding in devising personalized medicine approaches tailored to individual lipid profiles and health conditions. Such an approach could significantly enhance patient outcomes and reduce healthcare burdens related to cardiovascular diseases.

However, the study does not come without its limitations. While promising, the findings are primarily derived from preclinical models, and further research is needed to translate these insights into human applications. Larger scale clinical trials are essential to investigate the efficacy and safety of potential therapies that target β2GPI or the HDL regulatory pathways.

Additionally, researchers must consider the multifactorial nature of cardiovascular diseases. Lifestyle factors, genetic predispositions, and additional biomarkers will play a critical role in shaping treatment strategies. As such, future investigations should not only focus solely on HDL-regulating proteins but also integrate a broader perspective that encompasses environmental, genetic, and lifestyle determinants.

The work of Wang et al. serves as a newfound lens into the intricate world of lipid metabolism, emphasizing how regulatory proteins like β2GPI can influence cardiovascular health. By building a comprehensive understanding of these relationships, we open up avenues for innovative clinical strategies that may one day improve health outcomes for countless individuals at risk of cardiovascular diseases.

In summary, the findings presented by Wang and his team herald a significant step forward in our understanding of HDL biology and its regulation by βeta-2 glycoprotein I. The study not only underlines the importance of nuanced, sex-based approaches to medical research but also reinforces the need for continued exploration into the underlying mechanisms of lipid metabolism and cardiovascular health. As we seek to tailor future interventions that address these complex interactions, the lessons learned from this research impart invaluable insight into the evolving landscape of cardiovascular medicine.

Understanding the implications of such studies will be pivotal in shaping future guidelines and strategies in managing cardiovascular diseases across different populations, particularly in women who often experience distinct cardiovascular health challenges.

In conclusion, ongoing research into HDL particles and the proteins that regulate them, such as β2GPI, will yield important findings that could redefine our approaches to cardiovascular therapeutics and enhance health outcomes for individuals facing cardiovascular disease threats.

Subject of Research: The Role of βeta-2 Glycoprotein I in Regulating Apolipoprotein E-containing HDL Particles in Females

Article Title: βeta-2 glycoprotein I is a novel regulator of Apolipoprotein E containing HDL particles in females.

Article References: Wang, Y., Qi, M., Chen, L. et al. βeta-2 glycoprotein I is a novel regulator of Apolipoprotein E containing HDL particles in females. Biol Sex Differ 16, 80 (2025). https://doi.org/10.1186/s13293-025-00766-9

Image Credits: AI Generated

DOI: 10.1186/s13293-025-00766-9

Keywords: Apolipoprotein E, High-Density Lipoprotein, βeta-2 Glycoprotein I, Cardiovascular Health, Lipid Metabolism, Female Physiology, Inflammation, Therapeutic Strategies, Cholesterol Transport, Disease Prevention.

Conventional thinking held that HDLs remove cellular cholesterol primarily through passive diffusion. However, this paradigm was challenged by genetic insights gleaned from studies of Tangier disease, a rare inherited disorder marked by markedly reduced plasma HDL levels. These studies identified ATP-binding cassette protein A1 (ABCA1), an ATP-dependent transmembrane transporter, as essential for efficient HDL biosynthesis. The discovery raised profound questions about the mechanistic underpinnings of HDL biogenesis: How does ABCA1 harness ATP hydrolysis to mobilize cholesterol and phospholipids? What conformational states does ABCA1 adopt during HDL generation, and how does its extracellular domain participate in this process?

Harnessing cutting-edge high-speed atomic force microscopy (HS-AFM), a research collaboration led by Professor Kazumitsu Ueda at Kyoto University’s Institute for Integrated Cell-Material Sciences (iCeMS) teamed up with experts at Kanazawa University to shed light on these questions. HS-AFM enables real-time visualization of biomolecular activities with nanometer spatial resolution and sub-second temporal precision, an advancement that surpasses classical cryoelectron microscopy by capturing dynamic conformational changes in native-like environments. This unprecedented imaging capability allowed the team to monitor ABCA1’s behavior at the membrane interface during nascent HDL formation, providing an intimate view of lipid transport and complex assembly that had never before been observed.

Initial hypotheses posited that ABCA1’s extracellular domain (ECD) served as a static lipid reservoir, temporarily accommodating approximately 500 cholesterol and phospholipid molecules on its outer face. However, early structural data from cryoelectron microscopy suggested that the ECD forms a narrow tunnel structure, seemingly incongruent with the volume necessary to harbor such a large number of lipids. This discrepancy hinted at a more intricate mechanism involving dynamic structural reorganization. Using HS-AFM, Ueda’s team visualized that rather than sitting passively, the ECD actively undergoes conformational remodeling during lipid translocation, expanding and subsequently reducing its volume by nearly 30% as it loads lipids en masse.

The process begins as ABCA1 hydrolyzes ATP molecules, harnessing the energy released to power the translocation of lipid molecules from the inner leaflet of the plasma membrane through the transmembrane regions and into the ECD. The researchers observed that the ECD temporarily “inflates,” generating novel structural features capable of storing a substantial lipid payload. These lipids are then transferred collectively onto apolipoprotein A-I (apoA-I), a protein that serves as a lipid acceptor and scaffold for HDL particle assembly. This cooperative loading mechanism culminates in the formation of nascent HDL particles, which are subsequently released into circulation to fulfill their cholesterol-scavenging functions.

This newfound insight into the dynamic lipid handling by ABCA1 challenges prior models of HDL formation that relied heavily on simplistic diffusion or tunnel-based lipid transfer. Instead, it illuminates a sophisticated energy-dependent cycle of membrane remodeling and lipid packaging orchestrated by ABCA1’s ATP-driven conformational flexibility. Such a paradigm shift expands our fundamental grasp of cholesterol metabolism and opens new avenues for therapeutic modulation targeting the structural states of ABCA1, potentially enhancing HDL biogenesis or correcting defects seen in dyslipidemic conditions.

Moreover, the HS-AFM methodology employed in this study represents a remarkable technical breakthrough. The ability to perform direct side-view imaging of membrane proteins, particularly large transporters like ABCA1, remains an exceptionally challenging feat. By overcoming these hurdles, the research introduces a versatile platform that can be extended to investigate a broad spectrum of biological transporters involved in lipid trafficking, drug extrusion, and metabolic waste removal, significantly enriching our structural and functional understanding of membrane proteins critical to health and disease.

Professor Ueda emphasizes the clinical and biological ramifications of these findings: “Our detailed visualization of ABCA1-mediated HDL formation helps clarify the physiological roles of HDL and cholesterol, elements often misunderstood in cardiovascular research. By elucidating the regulatory mechanisms that guide ABCA1 function, we anticipate more precise targeting in the development of therapies for cholesterol-related disorders.” This pioneering work thus bridges a long-standing knowledge gap, with the potential to reshape strategies in combating atherosclerosis and related cardiovascular conditions.

In addition to the academic impact, the team demonstrates the power of interdisciplinary collaboration, leveraging the precision of nano-scale imaging with biochemical expertise to tackle complex biological questions that were once inaccessible. The combined efforts of Kyoto University and Kanazawa University scientists accentuate the promise of emerging imaging technologies in unraveling intricate molecular phenomena.

Moving forward, these revelations could inspire innovative therapeutic approaches aimed at modulating ABCA1 activity or stabilizing particular conformational states to optimize HDL generation. Furthermore, understanding the nuanced interplay between “good” HDL cholesterol and “bad” low-density lipoproteins (LDL) within the vascular milieu may eventually yield comprehensive treatments that address the multifactorial nature of cholesterol-driven disease pathogenesis.

This study’s broader contributions extend beyond cardiovascular health; the ability to monitor membrane protein dynamics live and in situ could inform the design of novel interventions across diverse fields including metabolic regulation, drug resistance, and membrane biology. Consequently, the implications of this work resonate well beyond the confines of lipid metabolism, establishing new frontiers in molecular medicine.

The authors have made available supplementary video content capturing the real-time structural dynamics of ABCA1 during lipid transfer, providing compelling visual evidence of these molecular events. These materials not only enhance scientific transparency but also serve as valuable educational tools for the broader research community.

As technology continues to advance, the integration of high-speed atomic force microscopy with complementary biophysical techniques is poised to deepen our mechanistic understanding of cellular transport processes. Ultimately, such insights pave the way for precision medicine strategies tailored to correct or augment fundamental biological pathways at the molecular level.

Subject of Research: Molecular mechanism of HDL biogenesis mediated by ATP-binding cassette protein A1 (ABCA1)

Article Title: Direct Visualization of ATP-Binding Cassette Protein A1 Mediated Nascent High-Density Lipoprotein Biogenesis by High-Speed Atomic Force Microscopy

News Publication Date: 20-Aug-2025

Web References: http://dx.doi.org/10.1021/acs.nanolett.5c03116

References: Kodan et al., Nano Letters, 2025

Image Credits: The Authors

Keywords: Cell biology, Molecular biology, Biochemistry, Atomic force microscopy, Dyslipidemia